1
Clinical Trials associated with Nanobody-based biepitope BCMA-targeting CAR-T cells(Wuhan Union Hospital)A Multicenter Clinical Study on the Safety and Efficacy of Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of Relapsed/Refractory Multiple Myeloma
To explore the safety and efficacy of nanobody-based BCMA-targeting biepitope CAR-T cells in the treatment of relapsed/refractory multiple myeloma,this study will be conducted in multiple study centers, with 60 patients openly enrolled to receive CAR-T cell therapy. Patients participating in clinical trials will be tested and evaluated for treatment safety, efficacy, duration of response, and long-term survival.
100 Clinical Results associated with Nanobody-based biepitope BCMA-targeting CAR-T cells(Wuhan Union Hospital)
100 Translational Medicine associated with Nanobody-based biepitope BCMA-targeting CAR-T cells(Wuhan Union Hospital)
100 Patents (Medical) associated with Nanobody-based biepitope BCMA-targeting CAR-T cells(Wuhan Union Hospital)
100 Deals associated with Nanobody-based biepitope BCMA-targeting CAR-T cells(Wuhan Union Hospital)